Opening Session Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Cost of Care

The ASCO Post Staff

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

May

Today In Oncology

Opening Session Panel Discussion

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Recent Rates of Systemic Treatment for Metastatic NSCLC in Older Adults

Whole-Genome Sequencing Test Enables Genomically Informed Treatment Decision-Making in Multiple Myeloma

Early-Onset Lung Cancer May Be Connected to Pesticide Contaminants

Noninvasive Urine Test May Provide Grade Group Information in Patients With Prostate Cancer